300039.SZ SHZ
Shanghai Kaibao Pharmaceutical CO.,Ltd
1W: +0.0%
1M: -2.8%
3M: +18.6%
YTD: -18.8%
1Y: -19.9%
3Y: -18.3%
5Y: +14.0%
¥5.30 ($0.79)
+0.15 (+2.91%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$1.5B
-7.6% ▼
5Y CAGR: +0.8%
Gross Profit
$1.2B
-6.4% ▼
5Y CAGR: +0.6%
Operating Income
$438M
+14.4% ▲
5Y CAGR: +7.7%
Net Income
$376M
+14.6% ▲
5Y CAGR: +8.4%
EPS (Diluted)
$0.36
+16.1% ▲
5Y CAGR: +8.4%
EBITDA
$470M
+28.0% ▲
5Y CAGR: +6.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $908M | $1.1B | $1.1B | $1.6B | $1.5B |
| YoY Growth | -36.0% | +21.2% | +1.7% | +42.5% | -7.6% |
| Cost of Revenue | $180M | $235M | $248M | $312M | $273M |
| Gross Profit | $728M | $866M | $871M | $1.3B | $1.2B |
| Gross Margin | 80.2% | 78.7% | 77.9% | 80.4% | 81.5% |
| R&D Expenses | $59M | $79M | $53M | $96M | $100M |
| SG&A Expenses | $547M | $616M | $573M | $820M | $590M |
| Operating Expenses | $633M | $732M | $667M | $899M | $762M |
| Operating Income | $134M | $172M | $228M | $383M | $438M |
| Operating Margin | 14.8% | 15.6% | 20.4% | 24.0% | 29.7% |
| Interest Expense | $516K | $148K | $127K | $119K | $149K |
| Income Before Tax | $132M | $170M | $226M | $384M | $434M |
| Tax Expense | $25M | $30M | $36M | $57M | $59M |
| Net Income | $106M | $140M | $191M | $328M | $376M |
| Net Margin | 11.7% | 12.7% | 17.1% | 20.6% | 25.5% |
| EPS (Diluted) | $0.10 | $0.13 | $0.18 | $0.31 | $0.36 |
| EBITDA | $173M | $204M | $258M | $368M | $470M |
| Shares Outstanding | 1.05B | 1.05B | 1.05B | 1.05B | 1.05B |